<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">SIMVASTATIN</span><br/>(sim-vah-sta'-tin)<br/><span class="topboxtradename">Zocor<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">antilipemic</span>; <span class="classification">hmg-coa reductase inhibitor (statin)</span><br/><b>Prototype: </b>Lovastatin<br/><b>Pregnancy Category: </b>X<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5 mg, 10 mg, 20 mg, 40 mg, 80 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase; similar in action to lovastatin but more potent. HMG-CoA
         reductase inhibitors increase HDL cholesterol, and decrease LDL cholesterol, and total cholesterol synthesis.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Indicated by decreased serum triglycerides, decreased LDL, cholesterol, and modest increases in HDL cholesterol.</p>
<h1><a name="uses">Uses</a></h1>
<p>Hypercholesterolemia (alone or in combination with bile acid sequestrants), familial hypercholesterolemia. Reduces risk of
         coronary death and nonfatal MI.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to simvastatin; active liver disease; pregnancy (category X), lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Homozygous familial hypercholesterolemia, history of liver disease, alcoholics. Safety and effectiveness in children and adolescents
         are not established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypercholesterolemia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 540 mg q.d. (max: 80 mg q.d.). Patients taking danazol or cyclosporine should not exceed 10 mg q.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Adjust dosage usually at 4-wk intervals.</li>
<li>Give in the evening.</li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CV:</span> Angina. <span class="typehead">CNS:</span> Dizziness, headache, vertigo, asthenia, fatigue, insomnia. <span class="typehead">GI:</span> Nausea, diarrhea, vomiting, abdominal pain, constipation, flatulence, heartburn, transient elevations in liver transaminases,
      transient elevations in CPK. <span class="typehead">Body as a Whole:</span> Fatigue. <span class="typehead">Respiratory:</span> Rhinitis, cough. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May increase PT when administered with <b>warfarin;</b>
<b>cyclosporine,</b>
<b>gemfibrozil,</b>
<b>fenofibrate,</b>
<b>clofibrate,</b> antilipemic doses of <b>niacin,</b>
<b>fluconazole,</b>
<b>itraconazole,</b>
<b>ketoconazole,</b>
<b>miconazole,</b>
<b>nefazodone,</b>
<b>nelfinavir,</b>
<b>ritonavir,</b>
<b>saquinavir,</b>
<b>sildenafil,</b>
<b>tacrolimus, clarithromycin, erythromycin, telithromycin</b> may increase serum levels and increase risk of myopathy, rhabdomyolysis and acute kidney failure. <span class="typehead">Food:</span>
<b>Grapefruit juice</b> (&gt;1 quart daily) may increase risk of myopathy, rhabdomyolysis. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract. <span class="typehead">Onset:</span> 2 wk. <span class="typehead">Peak:</span> 46 wk. <span class="typehead">Distribution:</span> 95% protein bound; achieves high liver concentrations; crosses placenta. <span class="typehead">Metabolism:</span> Extensive first-pass metabolism in liver to its active metabolite. <span class="typehead">Elimination:</span> 13% excreted in urine, 60% in bile and feces. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Obtain baseline and periodic (q6mo) liver function during the first year and yearly thereafter. Monitor cholesterol
            levels throughout therapy.
         </li>
<li>Monitor coagulation studies with patients receiving concurrent warfarin therapy. PT may be prolonged.</li>
<li>Assess for and report unexplained muscle pain. Determine CPK level at onset of muscle pain.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report unexplained muscle pain, tenderness, or weakness, especially if accompanied by malaise or fever, to physician.</li>
<li>Report signs of bleeding to physician promptly when taking concurrent warfarin.</li>
<li>Moderate intake of grapefruit juice while taking this medication.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>